IDE supported by data from the MODERATO II randomized pilot study that showed AVIM therapy drove significant and sustained reductions in blood pressure in hypertensive pacemaker patients
Orchestra BioMed Holdings, Inc. (NASDAQ: OBIO) watched its shares soar Tuesday, as the company, a biomedical concern accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced the U.S. Food and Drug Administration .
Orchestra BioMed (OBIO) Granted FDA Approval of IDE to Initiate BACKBEAT Pivotal Study of BackBeat CNT streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Shares of Orchestra BioMed Holdings, Inc. (OBIO) are rising over 17% on Tuesday after FDA approved an investigational device exemption (IDE) to initiate the global pivotal BACKBEAT (BradycArdia paCemaKer with atrioventricular interval modulation for Blood prEssure treAtmenT) study.
Motus GI Appoints Medical Device Industry Veteran Scott Durbin to its Board of Directors itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.